INIS
patients
100%
lymphomas
75%
populations
33%
diseases
31%
risks
28%
stem cells
24%
blood
23%
therapy
21%
comparative evaluations
20%
transplants
19%
netherlands
18%
hazards
16%
myeloid leukemia
14%
mortality
14%
leukemia
14%
refractories
13%
chemotherapy
12%
doses
12%
adults
11%
quality of life
11%
grafts
11%
cancer
10%
data
9%
host
9%
receptors
8%
cyclophosphamide
7%
antigens
7%
toxicity
7%
death
6%
malignancies
6%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
28%
Overall Survival
25%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Acute Myeloid Leukemia
18%
Netherlands
17%
Hazard Ratio
16%
Marrow Transplantation
15%
Confidence Interval
15%
Peripheral T-cell Lymphoma
13%
Lymphoma
13%
Relapsed or Refractory
11%
Rituximab
11%
Lymphoma Patients
10%
Older Patients
10%
Leukemia Risk
9%
Graft-versus-host Disease (GvHD)
9%
Population-based
9%
Disease-free Survival
8%
Chemotherapy
8%
Elderly Patients
8%
Health-related Quality of Life
8%
Large B-cell Lymphoma
8%
Progression-free Survival
8%
Chimeric Antigen Receptor T Cells (CAR-T)
8%
High-risk MDS
7%
Intensive Care Medicine
7%
Primary Central Nervous System Lymphoma (PCNSL)
7%
Hematopoietic Stem Cell Transplantation
7%
Reduced-intensity Conditioning
7%
Cancer Registry
7%
Medicine and Dentistry
Overall Survival
30%
Hazard Ratio
16%
Myelodysplastic Syndrome
15%
Hematopoietic Cell
15%
Cell Transplantation
15%
Acute Myeloid Leukemia
13%
Diffuse Large B-Cell Lymphoma
12%
Peripheral T-Cell Lymphoma
11%
Diseases
10%
Quality of Life
10%
Cohort Analysis
10%
Progression Free Survival
9%
Disease Free Survival
9%
Rituximab
8%
Arm
8%
Large-Cell Lymphoma
8%
Chimeric Antigen Receptor T-Cell
7%
Autologous Stem Cell Transplantation
7%
Cancer Registry
6%
Comorbidity
6%
Methotrexate
6%
Anaplastic Large Cell Lymphoma
6%
Angioimmunoblastic T-Cell Lymphoma
5%
Decision Making
5%
Fludarabine
5%
Myelofibrosis
5%
Reduced Intensity Conditioning
5%
Allogeneic Hematopoietic Stem Cell Transplantation
5%
Minimal Residual Disease
5%